Downloads

1. O’Brien JR. The adhesiveness of native platelets and its prevention. J Clin Pathol 1961;14:140-149. 2. Panzer S, Höcker L, Koren D. Agonists-induced platelet activation varies considerably in healthy male individuals: studies by flow cytometry. Annals of hematology. 2006;85(2):121-125. 3. Jones CI, Garner SF, Angenent W, et al. Mapping the platelet profile for functional genomic studies and demonstra- tion of the effect size of the GP6 locus. J Thromb Haemost 2007;5(8):1756-1765. 4. Jones CI, Bray S, Garner SF, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114(7):1405-1416. 5. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. American Medical Association. 2019;321(3):277-287. 6. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. European heart journal 2019;40(7):607–617. 7. Palmerini T. Benedetto U. Bacchi-Reggiani L. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. The Lancet. 2015;385(9985):2371-2382. 8. Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT durationPloS one. 2017;12(9) 9. Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely de- spite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co- medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872-9. 10. Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016;388(10055):2015-2022. 11. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9. 12. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. 13. Jover E, Rodriguez JM, Bernal A et al. High on-treatment platelet reactivity in patients with ischemic cerebrovas- cular disease: assessment of prevalence and stability over time using four platelet function tests. Blood Coagul Fibrinolysis. 2014;25(6):604-11. 14. Bye AP, Unsworth AJ, Gibbins JM. Platelet signaling: a complex interplay between inhibitory and activatory net- works. J Thromb Haemost. 2016;14(5):918-30. 15. Goodall AH, Burns P, Salles I et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 2010;116(22):4646-4656. 16. Garner SF, Furnell A, Kahan BC et al. Platelet responses to agonists in a cohort of highly characterised platelet donors are consistent over time. Vox sanguinis. 2017;112(1):18-24. 17. Leopold JA, Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circulation research. 2018;122(9):1302-1315. 18. Lordkipanidzé M, Lowe GC, Kirkby NS et al. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. Blood 2014;123(8):e11-e22. 19. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Elsevier. 2009. 20. Voors-Pette C, Lebozec K, Dogterom, P, et al. Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019;39(5):956-964. 21. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antag- onist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68(3):249-58. 22. Estevez B, Shen B, Du X. Targeting integrin and integrin signaling in treating thrombosis. Arterioscler Thromb Vasc Biol. 2015;35(1):24-9. 23. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99(3):466-72. 24. Stefanini L, Bergmeier W. RAP1-GTPase signaling and platelet function. J Mol Med (Berl). 2016;94(1):13-9. 25. Stuckey TD, Kirtane AJ, Brodie BR, et al. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017;10(16):1607-1617. 26. Cattaneo M. High on-treatment platelet reactivity–definition and measurement. Thromb Haemost. 2013;109(5):792- 8. 27. Petersen R, Lambourne JJ, Javierre BM, et al. Platelet function is modified by common sequence variation in megakaryocyte super enhancers. Nat Commun. 2017;8:16058. 28. Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inher- ited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007;92(3):357- 65. 29. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007;5(8):1617-1623. 30. O’Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001;103(5):3051-2056